key: cord-0024681-vy5gjltv
authors: Duan, Yanfen; Zhang, Dongning; Ye, Yan; Zheng, Sili; Huang, Ping; Zhang, Fengyun; Mo, Guoyan; Huang, Fang; Yin, Qiang; Li, Jingjing; Han, Lintao
title: Integrated Metabolomics and Network Pharmacology to Establish the Action Mechanism of Qingrekasen Granule for Treating Nephrotic Syndrome
date: 2021-12-06
journal: Front Pharmacol
DOI: 10.3389/fphar.2021.765563
sha: d4dd2d3b14e10eab0d891b506b74e48bd85457fe
doc_id: 24681
cord_uid: vy5gjltv

Nephrotic syndrome (NS) is a clinical syndrome resulting from abnormal glomerular permeability, mainly manifesting as edema and proteinuria. Qingrekasen granule (QRKSG), a Chinese Uyghur folk medicine, is a single-flavor preparation made from chicory (Cichorium intybus L.), widely used in treating dysuria and edema. Chicory, the main component in QRKSG, effectively treats edema and protects kidneys. However, the active components in QRKSG and its underlying mechanism for treating NS remain unclear. This study explored the specific mechanism and composition of QRKSG on an NS rat model using integrated metabolomics and network pharmacology. First, metabolomics explored the relevant metabolic pathways impacted by QRKSG in the treatment of NS. Secondly, network pharmacology further explored the possible metabolite targets. Afterward, a comprehensive network was constructed using the results from the network pharmacology and metabolomics analysis. Finally, the interactions between the active components and targets were predicted by molecular docking, and the differential expression levels of the target protein were verified by Western blotting. The metabolomics results showed “D-Glutamine and D-glutamate metabolism” and “Alanine, aspartate, and glutamate metabolism” as the main targeted metabolic pathways for treating NS in rats. AKT1, BCL2L1, CASP3, and MTOR were the core QRKSG targets in the treatment of NS. Molecular docking revealed that these core targets have a strong affinity for flavonoids, terpenoids, and phenolic acids. Moreover, the expression levels of p-PI3K, p-AKT1, p-mTOR, and CASP3 in the QRKSG group significantly decreased, while BCL2L1 increased compared to the model group. These findings established the underlying mechanism of QRKSG, such as promoting autophagy and anti-apoptosis through the expression of AKT1, CASP3, BCL2L1, and mTOR to protect podocytes and maintain renal tubular function.

Nephrotic syndrome (NS) is a clinical condition caused by inflammation, oxidative stress, immune injury, and podocyte damage in the kidney (Imig and Ryan, 2013; Zhang et al., 2018) . The disease is characterized by edema, proteinuria, hypoalbuminemia, and hyperlipidemia, due to abnormal glomerular permeability (Wang and Greenbaum, 2019; Tsuji et al., 2020) . The current treatments for NS are extensive, repetitive, non-specific, and have side effects because of the understanding of the biological processes leading to NS (Saleem, 2019) . Thus, NS is often accompanied by various complications, complicated treatment procedures, and unsatisfactory curative effects. Eventually, NS develops into renal failure, which negatively impacts livelihoods and the economy (Wang et al., 2000) . Considering the far-reaching impacts of NS, it is essential to establish NS-related mechanisms and suitable drugs. Recently, many patients with kidney diseases have resorted to traditional Chinese medicines (TCM) (Zhao et al., 2015) , whose biological activity and therapeutic effects are proven in vitro and animal experiments (Fang et al., 2013; Zhang et al., 2014) . Chicory (Cichorium intybus L.), is a medicinal plant widely distributed in Europe, America, and Asia, and the main components of Qingrekasen Granule (QRKSG), listed in the Pharmacopoeia of the People's Republic of China (2020 edition). The plant functions as a diuretic, anti-inflammatory, digestive, cardiotonic, and liver tonic (Petrovic et al., 2004; Satmbekova et al., 2018) . Moreover, the sesquiterpene lactones 8-Deoxylactucin, lactucin, and lactucopicrin in chicory extract inhibit the production of prostaglandin E2 (PGE2) and COX-2 protein expression (Cavin et al., 2005) , hence, reducing incidences of edema and inflammatory pain (Wesolowska et al., 2006) . For example, the chicory extract reduces carrageenan-induced paw edema (Rizvi et al., 2014) . The extract significantly reduces α1microglobulin in urine, improves histological appearance, and repairs kidney damage (Pourfarjam et al., 2017) . QRKSG is a granule made from chicory, and is approved by the China Food and Drug Administration, approval number (CFDA approval no. Z65020172). However, the functional mechanisms and value of QRKSG in NS are unknown.

Metabolomics and network pharmacology are two disciplines for understanding the mechanisms of drug action by linking the metabolites to disease targets. Metabolomics detect metabolic changes (Majumder et al., 2021) and the positive role of metabolites in physiology and disease development in organisms (Rinschen et al., 2019) . In TCM, metabolomics revealed the mechanisms of various prescriptions, including the Qi-Dan Fang Granule (Wu et al., 2014) and the Danggui-Shaoyao-San (Wang et al., 2020) . Meanwhile, network pharmacology predicts the possibility of drug compounddisease target combinations and pathway analysis (Xiong et al., 2019; Xiong et al., 2020) . Thus, the approach is suitable for analyzing TCM preparations . For example, a new method of treating osteoarthritis has been established using network pharmacological analysis thus, strengthening evidence-based research and promoting the development of high-quality Chinese medicine (Li and Zhang, 2013) .

The findings in this research form a basis for clinical approval and QRKSG use for managing NS. The flow chart of the research process is shown in Figure 1 .

The Qingrekasen Granule was purchased from Xinjiang Uygur Pharmaceutical Co., Ltd. (NO.1807521, Xinjiang, China) . Adriamycin (ADR) was purchased from Shenzhen Main Luck Pharmaceuticals Inc. (No. 2007E1, Shenzhen, China) , and Benazepril was purchased from Novartis (No. 2007, Beijing, China) . The BCA Protein Assay Kit was obtained from Beyotime Biotech Inc. (P0012, Shanghai, China), and Guangzhou Jet Bio-Filtration Co., Ltd. (Guangzhou, China) provided the Elisa plates (12 well strip ×8). HPLC grade methanol and acetonitrile were purchased from Merck KGaA (Darmstadt, Germany). Anti-PI3K and anti-p-PI3K antibodies were purchased from Cell Signaling Technology Inc. (MA, United States). The Anti-AKT, anti-p-AKT, anti-mTOR, anti-P-mTOR, anti-BCL-2, anti-Caspase-3, and Beta-actin antibodies were purchased from Bioworld Technology Inc. (MN, United States). All other reagents were HPLC grade.

Thirty-two male SD (Sprague Dawley) rats (180-220 g) were obtained from Sibefu (Beijing) Biotechnology Co., Ltd. (YFY-2018-0,002, Beijing, China) . The SD rats were housed in an environmentally conditioned room with a 12 h light/dark cycle, at 25 ± 2°C, and 50 ± 5% relative humidity. All rats accessed drinking water and feed ad libitum. The protocols in this study strictly followed the animal ethics standards of the Hubei University of Chinese Medicine. After 1 week of acclimation, the rats were randomly assigned into four groups, including the control (n 8) and ADR (7 mg/kg) treatments [three groups (n 24)].

The NS model was induced by injecting normal saline through the tail vein (Frenk et al., 1955; Korzets et al., 1997) . A 24 h urine protein test was performed once a week for four experimental weeks. Mineral oil was added to the urine collection container to avoid evaporation. After successfully inducing the NS model, the ADR-treated rats were randomly assigned into three groups (n 8 per group): model, QRKSG (treated with a clinically equivalent dose of 1.62 g/kg/d), and benazepril (treated with a clinically equivalent dose of 0.9 mg/kg/d) groups. The control and model groups were treated with normal saline. All treatments were gavage administered once per day for 4 weeks, after which the animals were anesthetized, their kidneys were removed, and blood was collected from the abdominal aorta using a syringe.

One portion of the left kidney tissue from each rat was fixed in 4% paraformaldehyde impregnated wax, paraffin-embedded, and serially sectioned (4-7 μm). After staining, the kidney sections were imaged and photographed with a biomicroscope (Olympus BX53, Olympus Optical Co., Tokyo, Japan). Another portion of left kidney tissue (<1 mm 3 ) was fixed and post-fixed using 2.5% glutaraldehyde and 1% osmium tetroxide, respectively. The tissues were sequentially treated by ethanol acetone dehydration and acetone embedding infiltration overnight, embedded, sectioned (60-80 nm), uranium-lead double-stained, and finally observed by transmission electron microscopy (HT7700, Hitachi High-Technologies Corporation, Tokyo, Japan). Right kidney tissues were washed with saline, freeze-dried in liquid nitrogen on filter paper for 30 min, and stored in the refrigerator at −80°C.

The collected blood samples were incubated at 4°C for 30 min, and the serum was separated by centrifugation (3,000 rpm for 10 min) for subsequent analysis. A biochemical analyzer (Chemray240, Rayto, Guangdong, China) detected albumin (ALB), total triglycerides (TG), creatinine (Cr), total cholesterol (TC), total protein (TP), and urea nitrogen (BUN) levels in the serum. In addition, the urine samples were centrifuged, and the collected supernatant was stored at −80°C for further analysis. The 24 h urine total protein concentration was determined using the BCA Protein Assay Kit and microplate reader (Epoch, Bio Tek, VT, United States) following the manufacturer's instructions.

The right kidney tissues were thawed at room temperature. Approximately 600 μL of the right kidney tissue homogenate was extracted with methanol, vortexed for 1 min, and ultrasonically centrifuged for 10 min in centrifuge tubes sitting in an ice bath to obtain the metabolites. Afterward, the supernatant was concentrated through centrifugation and evaporated to dryness. The internal standards: 10 μL D27myristic acid (0.75 mg/ml) and 40 μL methoxyamine pyridine solution (40 mg/ml) were then added and maintained for 90 min. Finally, 80 μL of MSTFA+1% TMCS (Sigma-Aldrich, MO, United States) and 20 μL n-hexane were added for derivatization and derivatization reaction termination. After centrifugation, 1 μL of the supernatant was transferred to a micro bottle for subsequent analysis. The GC-MS was performed as previously described (Cao et al., 2020) , using Gas Chromatography-Mass Spectrometer (7,890B-5977B, Agilent Technologies, CA, United States) equipped with a DB-5MS quartz capillary column (0.25 mm × 30 mm, 0.25 μm). Analysis was performed using 1 µL injection volume with helium as the carrier gas (99.999%). The flow rate was 1.0 ml/min and a split ratio of 10:1. The column temperature was maintained at 60°C for 1 min, then increased at a rate of 10°C/ min up to 250°C and maintained at 250°C for 10 min. The injection temperature was 250°C, while that of the electron bombardment ion source was 230°C, with a solvent delay of 5.9 min and a scanning range of the mass spectrum at m/z 50.0-600.0.

The differential metabolites were identified by converting the GC-MS experimental data into compound retention time and relative peak area information using the Agilent Masshunter software. The online tool, MetaboAnalyst5.0 (Chong et al., 2018; Chong et al., 2019 ) (version 5.0), performed the principal component analysis (PCA) and partial least squares discriminant analysis (PLS-DA). The Pathway Analysis project in the online tool MetaboAnalyst5.0 analyzed metabolic pathways. Specified path analysis parameters included the visualization method using a scatter plot (testing significant features), the enrichment method using the hypergeometric test, the topology analysis approach using relative-betweenness centrality, and the reference metabolome technique using all compounds in the pathway library. Metabolites with p < 0.05 and VIP>1.0 were considered as potential biomarkers. The network analysis project in the MetaboAnalyst5.0 online tool performed the comprehensive metabolomic and network pharmacology analysis. Differential metabolites and differential metabolic genes were sequentially imported for analysis. Selected gene-metabolite interaction networks in the networks analysis options obtained the interaction between metabolites and targets.

A vacuum freeze dryer (Scientz-100F, Zhejiang, China) and grinder (MM 400, Retsch, Shanghai, China) were used to freeze-dry and crush the QRKSG. Afterward, 100 mg of the lyophilized powder was dissolved in methanol, vortexed six times, and refrigerated overnight at 4°C. The extracts were filtered for analysis on the UPLC-MS/MS system.

An integrated UPLC (NexeraX2, Shimadzu, Japan) and MS/MS (4500QTRAP, Applied Biosystems, MA, United States) performed the QRKSG qualitative analysis. The chromatographic separation was performed at room temperature on a chromatographic column (181.8 µm, 2.1 mm*100 mm, Agilent). For chromatographic analysis, the mobile phase A and B were pure water/0.1% formic acid and acetonitrile with a 0.35 ml/min flow rate. The flow was programmed to start with 95% A and 5% B; 1-9 min, 5%-95% B; 9-10 min 5% A, 95% B; 9-10 min 95% B; 10-11 min, 5.0% B; 11-14 min, 5.0% B. The column oven was set at 40°C, and the injection volume was 4 µL. The mass spectrometry conditions were: ion source, vortex spray, and element temperature at 550°C; spray voltage -positive ion mode (5,500 v)/negative ion mode (−4500 V); 50psi (GSI), 60psi (GSII), 25psi (CUR).

First, the QRKSG biological targets were obtained from the SwissTargetPrediction database (http://www. swisstargetprediction.ch/). Secondly, the NS biological targets were obtained from GeneCards (https://www.genecards.org/), a searchable and integrated human gene database (Safran et al., 2010) . Finally, the QRKSG target information for treating NS was obtained by interacting with the above two. The DAVID database (https://david.ncifcrf.gov/summary.jsp) was used as the functional annotation of gene ontologies (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways.

The complex relationship of the metabolites-targets-pathways network was constructed using Cytoscape3.8.0 to determine the underlying mechanism of QRKSG on NS.

The AKT1, mTOR, CASP3, and BCL2L1 three-dimensional (3D) structures, in. pdb format were obtained from the RCSB PDB database (https://www. rcsb.org/). The AutodockTools1.5.6 software deleted water, cleaned the protein, changed the forcefield on the .pdb file, saved it in .pdbqt format, and was the receptor ready to complete. The ChemOffice and Openbabe 2. 3.1L preserved the 2D structure of the QRKSG active ingredient ligands and generated energy-minimized 3D conformations, saved in. pdb format. AutodockTools1.5.6 converted the .pdb files to .pdbqt format, and the ligands were ready for finishing. 

The kidney tissues were thawed at 4°C in a refrigerator for protein extraction. Afterward, 20 mg of kidney tissues were homogenized with 200 μL lysis buffer. The total protein concentration was determined using the BCA kit (PICPI23225, Thermo Fisher Scientific, MA, United States) following the manufacturer's instructions. The proteins were separated using 10% SDS ammonium persulfate gel electrophoresis and transferred into Frontiers in Pharmacology | www.frontiersin.org December 2021 | Volume 12 | Article 765563 PVDF membranes. The membranes were blocked with 5% skimmed milk in TBST (Tris-buffered saline, 0.1% Tween 20) solution for 1 h at room temperature, followed by overnight incubation with the primary antibody PI3K (1:1,000 dilution), p-PI3K, AKT, p-AKT, mTOR, p-mTOR, BCL-2, Caspase-3 and reference Beta-actin (all 1:1,000 dilution) at 4°C. Next, the membranes were washed in TBST solution and incubated with Anti-Rabbit lgG conjugated to horseradish peroxidase (HRP) at 37°C for 1 h and washed in TSBT solution. The immune response area in the membranes was observed using the enhanced chemiluminescence (ECL) kit (WBKLS0100, Millipore, MA, United States) following the manufacturer's instruction. The density and immune response analysis was performed using the Tanon-5200 imaging system (Tanon Science and Technology Co. Ltd., Shanghai, China) and ImageJ Software (NIH, MD, United States).

All quantitative group data were analyzed using a one-way analysis of variance (ANOVA) and presented as mean ± standard deviation. p < 0.05 was considered statistically significant.

The TG, BUN, TC, and Cr levels in the model group serum increased, while ALB and TP decreased more than the control group. However, QRKSG treatment reduced the levels of TG, BUN, TC, and Cr in the serum, while the level of ALB and TP increased ( Figure 2) . The 24 h proteinuria assessment in the rats revealed that the proteins in urine gradually increased from week 1 to week 4 after the model was established (Figure 3 ).

In week one, the urine protein content in the control group was significantly lower than the ADR-treated group, indicating that the NS was successfully induced. However, the proteinuria content was not significantly different between QRKSG and benazepril groups in the first week compared to the model group. Nevertheless, the proteinuria content was significantly higher in the model than in the QRKSG group in the 3rd and 4th weeks (p < 0.001). In addition, the proteinuria level was higher in the QRKSG than in the benazepril group in the 4th week. However, the urine protein levels were reduced in the QRKSG and benazepril groups compared to the control.

The pathological changes in the kidney tissues were observed under the light microscope ( Figure 4) . The glomeruli and tubules structures were normal, and the control group had no visible damage. Nevertheless, the model group showed renal tubular abnormalities, dilation of the tubular lumen, and edema. However, the benazepril and QRKSG groups showed significantly reduced edema and morphological changes than the model group. Groups of rat glomerular podocytes were observed by transmission electron microscopy ( Figure 5) . The results showed that foot processes in the normal group were neatly aligned, structurally intact, and the basement membranes were uniformly thick. The model group had numerous diffused fusions in the foot processes, and the structure of the podocytes changed, consistent with the structural changes of podocytes during NS development (Smoyer and Mundel, 1998) . Moreover, the degree of fusion significantly reduced in the 

The kidney samples obtained from the control, model, benazepril, and QRKSG groups were analyzed by GC-MS, and the total ion current chromatograms (TIC) are shown in Figure 6 . The model and QRKSG groups showed a considerable degree of separation ( Figure 7C ). The PLS-DA R 2 ( 0.963) and Q 2 ( 0.885) indicate an excellent PLS-DA model for discrimination and prediction ( Figure 7D ). The kidney metabolism spectrum analysis by PCA and PLS-DA revealed that the metabolisms in QRKSG and benazepril groups ranged between the model and control groups. These results indicate that treatment caused normal metabolite levels in rat kidneys ( Figures 7A,B) .

Twenty-four metabolites were identified as potential QRKSG biomarkers in the NS treatment at p < 0.05 and VIP > 1. Fifteen of the 24 metabolites were up-regulated in the QRKSG group, and nine were down-regulated than the model group ( Table 1) . A heat map of the 24 metabolites showed that the differentially expressed metabolites in the QRKSG and benazepril groups changed significantly ( Figure 7E ). Differential metabolic pathway analysis was performed using the MetaboAnalyst5.0, with an impact value > 0.1 as the potential related metabolic pathway. The identified potential biomarkers mainly involved the metabolism of amino acids in the four main pathways: D-Glutamine and D-glutamate metabolism; alanine, aspartate, and glutamate metabolism; arginine and proline metabolism; and arginine biosynthesis ( Figure 7F ; Table 2 ).

Component analysis using UPLC-MS/MS identified 411 compounds, including 142 flavonoids, 149 phenolic acids, 16 terpenoids, 29 alkaloids, 27 lignans, and coumarins, 3 quinones, and 45 others were identified. Thirty components were relatively regulated in the QRKSG group based on their retention time and mass spectrum ( Table 3 and Supplementary Figure S1 ). Additionally, the size of the fan-shaped area for each compound in the fan diagram corresponded to the peak area (Supplementary Figure S2 ). The QRKSG group had the highest contents of Cynarin, Quercetin-4'-O-glucuronide, esculin, and Cichorium.

The GO functional enrichment analysis yielded 2502 GO enriched entries, including 2,257 (90.2%) BPs (biological processes), 75 (3.3%) CCs (cellular components), and 170 (6.8%) MFs (molecular functions). The Omicshare tool (http:// www.omicsshare.com) analyzed and visualized the GO enrichment analysis ( Figure 8A ) and the top 20 related, among the 153 pathways ( Figure 8B) 

The network diagram revealed 34 node interactions (6 pathways, 5 metabolites, 15 enzymes, and 8 targets) (Figure 9 ). The greater the degree, the more the connected edges, hence the node was more important in the network. The average degree of the candidate components was 8.52, with AKT1 (degree 26), GAPDH (degree 21), CASP3 (degree 21), SRC (degree 18), BCL2L1 (degree 15), and mTOR (degree 13). AKT1, BCL2L1, and mTOR were involved in the PI3K-Akt signaling pathway, protecting against ADR-induced podocyte liver damage (Dai et al., 2010) . Other targets, including the apoptosis-related proteins such as CASP3 and BCL2L1 (Pradeep and Srinivasan, 2018) , were related to renal tubular cell apoptosis (Ahmed et al., 2019) . Therefore, AKT1, BCL2L1, CASP3, and mTOR were the core QRKSG targets for treating NS. Moreover, L-Glutamic acid and ornithine (both degree 13) regulated multiple targets in the network diagram, indicating that QRKSG exerts therapeutic effects by regulating multiple metabolic pathways through multiple targets and metabolites.

First, the docking method was validated. The crystals of AKT1, CASP3, BCL2L1, and mTOR contained original ligands, including OR4 (AKT1), TQ8 (CASP3), H0Y (BCL2L1), and RAP (mTOR), respectively. The docking result ( Figures  10B-E, blue ligand) was near-identical to the actual results ( Figures 10B-E, red ligand) . The root-mean-square deviation (RMSD) of the conformation of the docked and the original ligands were 0.7740, 1.6423, 0.3114, and 0.5901, respectively. These RMSD were less than 2.0 Å, indicating a feasible, effective docking scheme. In this study, molecular docking verified that the QRKSG active compounds significantly regulate AKT1, CASP3, BCL2L1, and mTOR. The smaller the absolute value of the docking score between the compound and the target, the worse their binding activity (Gupta et al., 2018) . These findings revealed that AKT1, CASP3, and mTOR targets have a strong affinity for most compounds, including flavonoids, terpenoids, and phenolic acids. The absolute binding energy values between the compounds and the targets are over 4.25 ( Figure 10A) . The force analysis established that terpenoid Lactucin binds to AKT1 via five amino acids: ASN59, VAL-270, GLN-79, TRP-80, and SER-205 ( Figure 10F ), and to BCL2L1 via three amino acids: ARG-139, PHE-105, and TYR-101 ( Figure 10G ). To CASP3, terpenoid Lactucin binds to AKT1 via six amino acids: TYR-204, GLY-122, THR-166, HIS-121, MET-61, and THR-62 ( Figure 10H ), while to mTOR, binding occurs via five amino acids: GLU-2032, SER-2035, PHE-2108, TYR-2105, GLN-85 ( Figure 10I ).

The p-PI3K, PI3K, p-AKT1, AKT1, p-mTOR, mTOR, BCL-2, and CASP3 protein expressions were analyzed to reveal the potential mechanism of QRKSG in mediating autophagy and inhibiting apoptosis in rats with NS. The findings revealed that p-PI3K, p-AKT1, p-mTOR, and CASP3 increased, while and BCL-2 decreased in the model than the control group ( Figure 11A) . The greyscale quantification of each blot was performed, and the calculations of p-PI3K/PI3K, p-AKT1/ AKT1, P-mTOR/mTOR, CASP3/β-actin, and BCL-2/β-actin were presented (Figures 11B,C) . Besides, the expression of p-PI3K, p-AKT1, p-mTOR, and CASP3 decreased, while BCL2L1 increased in the QRKSG than the model group (p < 0.05). In contrast, the expression of p-PI3K, p-AKT1, p-mTOR, and CASP3 significantly increased, while BCL-2 decreased in the model than the control group (p < 0.05).

Adriamycin-induced nephropathy (AN) has been extensively studied to unravel the underlying processes leading to kidney damage (Burke et al., 1977; Lu et al., 2017) . In this study, the NS rat model was established by injecting ADR through the tail vein to induce NS, leading to an increased proteinuria content in the model than the control group. Renal histopathology results revealed significant morphological changes in the NS rat model manifesting as renal tubular abnormalities, dilation of kidney tubular lumen, edema, and diffuse fusion of foot processes, suggesting a successful NS modeling. The presence of proteins in the urine is a sign of podocyte damage, an indicator of glomerular filtration dysfunction, and damage of renal tubular reabsorption (Reiser et al., 2002) . However, QRKSG treatment significantly reduced proteinuria, which manifested as reduced edema, morphological changes, and foot processes fusion in the renal tubes of rats in the QRKSG than the model group. Therefore, QRKSG protected rats against NS. The GC-MS metabolomics established the changes in renal metabolism, thus revealing the mechanism of QRKSG for treating NS. Twenty-four metabolic biomarkers were identified between the model and QRKSG groups. These metabolites were mainly involved in D-glutamine and D-glutamate metabolism; alanine, aspartate, glutamate metabolism; arginine and proline metabolism. The levels of L-glutamine and L-glutamate decreased after QRKSG treatment, indicating that the metabolism of D-glutamine and D-glutamate were interrupted. This observation is consistent with other findings where glutamine and phenylalanine levels were down-regulated in idiopathic NS (Sedic et al., 2014) . Glutamine and glutamate are irreplaceable in FIGURE 9 | Metabolites-targets-pathways network.

Frontiers in Pharmacology | www.frontiersin.org December 2021 | Volume 12 | Article 765563 D-glutamine and D-glutamate metabolism. Glutamine is catalyzed to reversibly generate glutamate, which further generates α-ketoglutarate, participating in the tricarboxylic acid (TCA) cycle to produce adenosine triphosphate (ATP) (Bharadwaj et al., 2020) . Thus, contributing to material and energy production (Hakimi et al., 2016) . However, glutamine plays a different role as an essential amino acid in the cell cycle progression, activating the mammalian target of rapamycin (mTOR) and homeostasis activation of reactive oxygen species (ROS) (Still and Yuneva, 2017; Bernfeld and Foster, 2019) . Glutamine also regulates the mTOR pathway and coordinates various environmental factors regulating cell growth and homeostasis (Still and Yuneva, 2017; Pradeep and Srinivasan, 2018) . In addition, glutamine synthetase is important in renal ammonia metabolism, maintaining the acid-base balance in the whole body, essential for optimal health (Conjard et al., 2003; Verlander et al., 2013; Harris and Weiner, 2021) . In mice, glutamate inhibits the fusion of podocytes with ADR, nephropathy, cell apoptosis, renin expression and reduces urine albumin (Gu et al., 2012) . Besides, glutamate converts toxic ammonia into non-toxic glutamine, preventing ammonia poisoning (Tardito et al., 2015) . Therefore, QRKSG probably metabolized glutamine and glutamate, reducing the urine protein in rats with NS, thereby protecting the kidneys of these rats. Network pharmacology analysis using UPLC-MS/MS predicted 146 targets and 153 pathways, with the PI3K-Akt signaling pathway, and the AGE-RAGE signaling pathway in diabetic complications, as the main pathways. AKT1, CASP3, BCL2L1, and mTOR were identified as potential QRKSG therapeutic targets for NS treatment. The PI3K/AKT signaling pathway is key in mammalian cell differentiation, proliferation, apoptosis, survival, autophagy and is a pivotal regulator of autophagy (Yan et al., 2018; Kim et al., 2020) . PI3K phosphorylates AKT after activation, activates downstream signaling molecules such as mTOR, and exerts corresponding biological effects. mTOR is the core protein that determines the formation and maturation of autophagosomes . mTOR activation in the kidney promotes up-regulation of proinflammatory and pro-fibrotic factors, leading to tubular interstitial fibrosis and atrophy (Lieberthal and Levine, 2012) . In contrast, inhibiting mTOR activation protects the kidneys against podocyte apoptosis . Inhibiting the PI3K/ Akt/mTOR pathway induces autophagy (Tsai et al., 2015) , promoting cell health in response to various cell stresses and nutritional conditions and subsequently protecting cells from damage (Kitada et al., 2017) . For example, mTOR activation negatively regulates autophagy in several types of cells (Lindqvist et al., 2015; Liu et al., 2018) . Autophagy is key in preventing kidney diseases because it maintains homeostasis and the integrity of renal tubules (Peng et al., 2019) . Thus, upregulating autophagy is an efficient treatment strategy for kidney diseases (Bhatia and Choi, 2020) . Besides, autophagy substantially reduced renal inflammation and interstitial damage in a unilateral ureteral obstruction (UUO) model where mTOR inhibition significantly increased autophagy and suppressed UUO-induced inflammation (Du et al., 2017 ). In the model group, PI3K, AKT1, and mTOR expression levels increased in the QRKSG than the control group, indicating that the PI3K/Akt/mTOR signaling pathway was activated. However, QRKSG treatment inhibited the PI3K/Akt/mTOR signaling pathway, which indicates that QRKSG probably increased autophagy to prevent renal tubular interstitial fibrosis and atrophy. Bax, a member of the BCL-2 family, is up-regulated by p53 transactivation, while p53 transcriptionally suppresses BCL-2, thereby activating caspase-9 and subsequently caspase-3 (Wen et al., 2014; Wnek et al., 2017) . Increasing the ratio of BCL-2 to Bax achieves the anti-apoptotic function of BCL-2 (Castro- Gonzalez et al., 2021) , while the activation of caspase-3 promotes cell apoptosis (Sun et al., 2011) . In addition, Srinivasan and Pradeep established that increasing the apoptosis mediator Bax decreased BCL-2 in the kidneys of diabetic rats (Pradeep and Srinivasan, 2018) . Parallel to the present study, Osama et al. reported that paricalcitol and enalapril protective cells against streptozotocin (STZ)induced renal tubular cell apoptosis by reducing the caspase-3 expression and increasing BCL-2 expression (Pradeep and Srinivasan, 2018) . Wu et al. also established that Fang Qi Dan down-regulates the expression of Bax protein while increasing the BCL-2 protein, which protects podocytes, and restores the selective filtration function of the glomerulus (Wu et al., 2014) . The expression of CASP3 increased in the model group, while the expression level of BCL2L1 decreased (VS control group), indicating the increased ability of renal cell apoptosis. However, QRKSG treatment weakened the renal apoptotic capacity. These results indicate that QRKSG protects renal tubular cells against ADR-induced renal damage. The findings are consistent with previous research (Lieberthal and Levine, 2009; Kaushal et al., 2020; Zhou et al., 2020; Bhosale et al., 2021; El-Gowily et al., 2021) , and the relevant target graphs are shown in Supplementary Figure S3 . Therefore, QRKSG could promote autophagy and anti-apoptosis through the expression of AKT1, CASP3, BCL2L1, and mTOR, thereby conferring protection to the podocytes and maintaining renal function and tubular homeostasis.

Molecular docking revealed the mode of interaction between the active QRKSG components and target proteins in the kidneys, where most components are bound to core targets (AKT1, CASP3, BCL2L1, and mTOR). The comprehensive evaluation of the docking results initially revealed the QRKSG material basis FIGURE 11 | Western blot analysis of PI3K, AKT1, mTOR, BCL-2, and CASP3. (A) Representative images of PI3K, AKT1, mTOR, BCL-2, and CASP3 (B) PI3K, AKT1, and mTOR protein expressions (C) BCL-2 and CASP3 protein expressions. The data are presented as mean ± SD, **p < 0.05 shows comparison against the control group, while # p < 0.05 shows comparison against the model group.

Frontiers in Pharmacology | www.frontiersin.org December 2021 | Volume 12 | Article 765563 of treating NS. This observation has profound implications for exploring the molecular-level QRKSG mechanism of action.

A comprehensive analysis revealed 23 key targets related to five metabolites and six pathways. These potential targets were related to multiple QRKSG active components. Among the key targets, AKT1, MTOR, CASP3, and BCL2L1 were important for the QRKSG underlying mechanism in treating NS. Specifically, the potential QRKSG mechanisms include inhibiting cell apoptosis and increasing autophagy, D-Glutamine, and D-glutamate metabolism, reducing proteinuria and weakening kidney damage ( Figure 12) . Therefore, these findings on the potential underlying QRKSG mechanism provide a theoretical basis for QRKSG clinical application.

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding authors.

The animal study was reviewed and approved by the Experimental Animal Ethics Committee of Hubei University of Chinese Medicine.

QY, JL, and LH designed the study; YD, DZ, SZ, PH, FZ, and YY performed the research; GM and FH collected and analyzed the data; YD drafted the paper. 

Effects of Enalapril and Paricalcitol Treatment on Diabetic Nephropathy and Renal Expressions of TNF-α, P53, Caspase-3 and Bcl-2 in STZ-Induced Diabetic Rats

Glutamine as an Essential Amino Acid for KRas-Driven Cancer Cells

SARS-CoV-2 and Glutamine: SARS-CoV-2 Triggered Pathogenesis via Metabolic Reprograming of Glutamine in Host Cells

Iridin Induces G2/M Phase Cell Cycle Arrest and Extrinsic Apoptotic Cell Death through PI3K/AKT Signaling Pathway in AGS Gastric Cancer Cells

Integrative Transcriptomics and Metabolomics Analyses Provide Hepatotoxicity Mechanisms of Asarum

HIV Nef-Mediated Ubiquitination of BCL2: Implications in Autophagy and

Inhibition of the Expression and Activity of Cyclooxygenase-2 by Chicory Extract

MetaboAnalyst 4.0: towards More Transparent and Integrative Metabolomics Analysis

Using MetaboAnalyst 4.0 for Comprehensive and Integrative Metabolomics Data Analysis

Inhibition of Glutamine Synthetase in the Mouse Kidney: a Novel Mechanism of Adaptation to Metabolic Acidosis

Hepatocyte Growth Factor Signaling Ameliorates Podocyte Injury and Proteinuria

Protease-activated Receptor-2 Promotes Kidney Tubular Epithelial Inflammation by Inhibiting Autophagy via the PI3K/Akt/mTOR Signalling Pathway

Tioconazole and Chloroquine Act Synergistically to Combat Doxorubicin-Induced Toxicity via Inactivation of PI3K/AKT/mTOR Signaling Mediated ROS-dependent Apoptosis and Autophagic Flux Inhibition in MCF-7

Regulation of Podocalyxin Expression in the Kidney of Streptozotocin-Induced Diabetic Rats with Chinese Herbs (Yishen Capsule)

Experimental Nephrotic Syndrome Induced in Rats by Aminonucleoside; Renal Lesions and Body Electrolyte Composition

Functional Metabotropic Glutamate Receptors 1 and 5 Are Expressed in Murine Podocytes

Docking Techniques in Pharmacology: How Much Promising?

An Integrated Metabolic Atlas of Clear Cell Renal Cell Carcinoma

Sex Differences in Renal Ammonia Metabolism

Immune and Inflammatory Role in Renal Disease

Autophagy Function and Regulation in Kidney Disease

Autophagy and G2/M Phase Cell Cycle Arrest through PI3K/AKT/mTOR Pathway in AGS Human Gastric Cancer Cell

Regulating Autophagy as a Therapeutic Target for Diabetic Nephropathy

Pefloxacin in Adriamycin Induced Nephrotic Syndrome in the Rat

Tadalafil Integrates Nitric Oxide-Hydrogen Sulfide Signaling to Inhibit High Glucose-Induced Matrix Protein Synthesis in Podocytes

LncRNA DCST1-AS1 Accelerates the Proliferation, Metastasis and Autophagy of Hepatocellular Carcinoma Cell by AKT/mTOR Signaling Pathways

Traditional Chinese Medicine Network Pharmacology: Theory, Methodology and Application. Chin

Mammalian Target of Rapamycin and the Kidney. II. Pathophysiology and Therapeutic Implications

The Role of the Mammalian Target of Rapamycin (mTOR) in Renal Disease

Current Questions and Possible Controversies in Autophagy

The Activity and Role of Autophagy in the Pathogenesis of Diabetic Nephropathy

Frontiers in Pharmacology | www.frontiersin.org

Paeoniflorin Ameliorates Adriamycin-Induced Nephrotic Syndrome through the PPARγ/ ANGPTL4 Pathway In Vivo and Vitro

Cognitive Analysis of Metabolomics Data for Systems Biology

ATG5-mediated Autophagy Suppresses NF-Κb Signaling to Limit Epithelial Inflammatory Response to Kidney Injury

Effect of Cichorium Intybus L. Seed Extract on Renal Parameters in Experimentally Induced Early and Late Diabetes Type 2 in Rats

Alleviation of Oxidative Stress-Mediated Nephropathy by Dietary Fenugreek (Trigonella Foenum-Graecum) Seeds and Onion (Allium cepa) in Streptozotocin-Induced Diabetic Rats

Novel Concepts in Understanding and Management of Glomerular Proteinuria

Identification of Bioactive Metabolites Using Activity Metabolomics

Activity of Roots of Cichorium Intybus Due to its Inhibitory Effect on Various Cytokines and Antioxidant Activity

GeneCards Version 3: the Human Gene Integrator

Molecular Stratification of Idiopathic Nephrotic Syndrome

Chemical and Biological Studies on Cichorium Intybus L

Label-free Mass Spectrometric Profiling of Urinary Proteins and Metabolites from Paediatric Idiopathic Nephrotic Syndrome

Regulation of Podocyte Structure during the Development of Nephrotic Syndrome

Hopefully Devoted to Q: Targeting Glutamine Addiction in Cancer

Regulator of Calcineurin 1 (RCAN1) Facilitates Neuronal Apoptosis through Caspase-3 Activation

Glutamine Synthetase Activity Fuels Nucleotide Biosynthesis and Supports Growth of Glutamine-Restricted Glioblastoma

Autophagy through PI3K/Akt/mTOR Inactivation and Autophagy Suppression Enhances Licochalcone A-Induced Apoptosis of Human Cervical Cancer Cells

MicroRNAs as Biomarkers for Nephrotic Syndrome

Expression of Glutamine Synthetase in the Mouse Kidney: Localization in Multiple Epithelial Cell Types and Differential Regulation by Hypokalemia

Text Messaging for Disease Monitoring in Childhood Nephrotic Syndrome

Evaluation of the Mechanism of Danggui-Shaoyao-San in Regulating the Metabolome of Nephrotic Syndrome Based on Urinary Metabonomics and Bioinformatics Approaches

Progressive Adriamycin Nephropathy in Mice: Sequence of Histologic and Immunohistochemical Events

A Novel Strategy for Real-Time and In Situ Detection of Cytochrome C and Caspase-9 in Hela Cells during

Analgesic and Sedative Activities of Lactucin and Some Lactucin-like Guaianolides in Mice

Molecular and Immunohistochemical Expression of Apoptotic Proteins Bax, Bcl-2 and Caspase 3 in Infantile Hemangioma Tissues as an Effect of Propranolol Treatment

Qi-Dan Fang Ameliorates Adriamycin-Induced Nephrotic Syndrome Rat Model by Enhancing Renal Function and Inhibiting Podocyte Injury

Network Pharmacology-Based Research of Active Components of Albiziae Flos and Mechanisms of its Antidepressant Effect

Network Pharmacology-Based Research on the Active Component and Mechanism of the Antihepatoma Effect of Rubia Cordifolia L

Baicalein Induces Apoptosis and Autophagy of Breast Cancer Cells via Inhibiting PI3K/AKT Pathway In Vivo and Vitro

Attenuation of Diabetic Nephropathy by Chaihuang-Yishen Granule through Anti-inflammatory Mechanism in Streptozotocin-Induced Rat Model of Diabetics

Network Pharmacology Databases for Traditional Chinese Medicine: Review and Assessment

Metabolomics Coupled with System Pharmacology Reveal the Protective Effect of Total Flavonoids of Astragali Radix against Adriamycin-Induced Rat Nephropathy Model

Inhibition of Adriamycin-Induced Nephropathy in Rats by Herbs Based Kangshenoral Solution

Tanshinone I Attenuates the Malignant Biological Properties of Ovarian Cancer by Inducing Frontiers in Pharmacology | www

Apoptosis and Autophagy via the Inactivation of PI3K/AKT/mTOR Pathway

Network Pharmacology Identifies the Mechanisms of Action of Shaoyao Gancao Decoction in the Treatment of Osteoarthritis

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2021.765563/ full#supplementary-material Conflict of Interest: QY was employed by the company Xinjiang Uygur Pharmaceutical Co., Ltd.The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.Copyright © 2021 Duan, Zhang, Ye, Zheng, Huang, Zhang, Mo, Huang, Yin, Li and Han. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.